Concepedia

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, R. P. EDWARDS, Asunción García, Mark Crozier, David Irwin, Emma Barrett

International Journal of Gynecological Cancer · 2005 · 16 citations · 13 references

References

13

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

M. Piccart · JNCI Journal of the National Cancer Institute · 2000 · 1K citations · Full text

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

Ovarian carcinoma diagnosis

Barbara A. Goff, Lynn S. Mandel, Howard G. Muntz et al. · Cancer · 2000 · 503 citations · Full text

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

J.T. Thigpen, John A. Blessing, Harrison Ball et al. · Journal of Clinical Oncology · 1994 · 389 citations